Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma

Nayer, Hassan; Murphy, Kathleen M.; Hawkins, Anita L.; Long, Patricia P.; Gillison, Maura L.; Borowitz, Michael J.; Griffin, Constance A.

doi:10.1080/10428190600879896

Cited by 20 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,26 Even though p53 mutations have been detected more frequently in interdigitating cell sarcoma than other dendritic malignancies, the data are still overall controversial and the prognostic value of p53 mutations has not been established. 27 A recent analysis has also reported higher frequency of acetylated histone H3 (H3Ac) expression in interdigitating dendritic cell and Langerhans cell sarcoma, when compared to Langerhans cell histiocytosis, being considered as the benign variant of the neoplasm.…”

Section: Discussionmentioning

confidence: 99%

Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature

Liso

Pennelli

Lodovichetti

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Interdigitating dendritic cell sarcoma is an extremely rare tumor. The diagnosis is difficult and is based on clinical, pathological and immunohistochemical evaluation. Differential diagnosis includes melanoma, mesenchymal and hematological malignancies. The mainstay of treatment is surgery for limited disease and different chemotherapy combinations have been tested for advanced disease. No evidence from prospective trials is currently available. We report the case of a 59 year-old male patient who experienced axillary lymphadenopathy with initial diagnosis of large-cell lung cancer on tumor biopsy. He underwent surgical resection with radical intent. Pathological diagnosis of interdigitating dendritic cell sarcoma was obtained on surgical samples. Nine months after radical surgery, he experienced systemic recurrence of disease and underwent chemotherapy with epirubicin and ifosfamide for 4 courses. During chemotherapy, he developed brain disease progression and underwent whole-brain radiotherapy. Systemic progression was then observed and molecular characterization was performed. B-RAF evaluation resulted positive for V600E mutation and the patient was treated with Vemurafenib according to molecular findings. He thus obtained initial clinical benefit but eventually died of brain hemorrhage. In conclusion, we report a case of B-RAF mutation detected in an interdigitating dendritic cell sarcoma patient treated with targeted therapy. B-RAF pathway could have a role in pathogenesis and evolution of this rare disease and could open new perspectives of treatment

show abstract

Section: Discussionmentioning

confidence: 99%

Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature

Liso

Pennelli

Lodovichetti

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…The etiology of IDCS remains obscure. A previous study have suggested that BCL2 chromosomal translocation is associated with IDCS (9), but another study contradicts this (10). The most common lesion site of IDCS is in the lymph node.…”

Section: Discussionmentioning

confidence: 87%

Interdigitating dendritic cell sarcoma presenting in the kidney combined with retroperitoneal leiomyosarcoma: A case report and literature review

et al. 2013

View full text Add to dashboard Cite

Interdigitating dendritic cell sarcoma (IDCS) and retroperitoneal leiomyosarcoma are rare tumors. The optimal diagnosis, treatment and prognosis remain unknown. The current case report presents a 46-year-old male who exhibited with a left renal mass combined with a periprostatic mass. The patient underwent surgery twice, respectively for the resection of the two masses. The postoperative pathological examination confirmed the diagnosis of IDCS presenting in the kidney and retroperitoneal leiomyosarcoma in the pelvis. To the best of our knowledge, it is the first report of IDCS in the kidney and of the combined appearance of IDCS and retroperitoneal leiomyosarcoma in the same patient.

show abstract

“…Renal IDCS is an extremely rare malignant tumor, originating from dendritic cells, that primarily occurs in the lymph nodes. The pathogenesis of kidney IDCS is strongly associated with the chromosomal translocation of the B-cell lymphoma 2 protein 34,35 .…”

Section: Histopathological Factorsmentioning

confidence: 99%

Renal sarcoma – a rare parenchymal tumor with a very poor prognosis

Iorga¹,

Anghel²,

Marcu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Le sarcome rénal-une tumeur parenchymateuse rare avec un pronostic très mauvais Le but de cet article était d'analyser les caractéristiques pronostiques, la présentation clinique, le diagnostic et le traitement des sarcomes rénaux primaires. Une revue approfondie de la littérature a été réalisée à l'aide de la base de données PubMed. Les sarcomes du rein sont des tumeurs malignes très rares, avec un très mauvais pronostic par rapport aux autres sarcomes urogénitaux. Plusieurs types histologiques ont été rapportés, le type le plus courant étant le léiomyosarcome. Outre la résection chirurgicale complète à larges marges, des facteurs anatomiques, histologiques, moléculaires

show abstract

Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma

Cited by 20 publications

References 8 publications

Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature

Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature

Interdigitating dendritic cell sarcoma presenting in the kidney combined with retroperitoneal leiomyosarcoma: A case report and literature review

Renal sarcoma – a rare parenchymal tumor with a very poor prognosis

Contact Info

Product

Resources

About